GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (STU:17Q1) » Definitions » PB Ratio

Pharmaron Beijing Co (STU:17Q1) PB Ratio : 1.19 (As of Jun. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pharmaron Beijing Co PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-24), Pharmaron Beijing Co's share price is €1.08. Pharmaron Beijing Co's Book Value per Share for the quarter that ended in Mar. 2024 was €0.91. Hence, Pharmaron Beijing Co's PB Ratio of today is 1.19.

Good Sign:

Pharmaron Beijing Co Ltd stock PB Ratio (=2.78) is close to 10-year low of 2.56

The historical rank and industry rank for Pharmaron Beijing Co's PB Ratio or its related term are showing as below:

STU:17Q1' s PB Ratio Range Over the Past 10 Years
Min: 2.56   Med: 8.71   Max: 18.75
Current: 2.78

During the past 10 years, Pharmaron Beijing Co's highest PB Ratio was 18.75. The lowest was 2.56. And the median was 8.71.

STU:17Q1's PB Ratio is ranked worse than
57% of 1300 companies
in the Biotechnology industry
Industry Median: 2.345 vs STU:17Q1: 2.78

During the past 12 months, Pharmaron Beijing Co's average Book Value Per Share Growth Rate was 15.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 12.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 25.80% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Pharmaron Beijing Co was 48.90% per year. The lowest was 10.80% per year. And the median was 46.55% per year.

Back to Basics: PB Ratio


Pharmaron Beijing Co PB Ratio Historical Data

The historical data trend for Pharmaron Beijing Co's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co PB Ratio Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 7.33 5.34 1.99

Pharmaron Beijing Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.04 2.23 2.60 1.99 1.22

Competitive Comparison of Pharmaron Beijing Co's PB Ratio

For the Biotechnology subindustry, Pharmaron Beijing Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaron Beijing Co's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's PB Ratio falls into.



Pharmaron Beijing Co PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Pharmaron Beijing Co's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=1.08/0.907
=1.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Pharmaron Beijing Co  (STU:17Q1) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Pharmaron Beijing Co PB Ratio Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaron Beijing Co (STU:17Q1) Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.

Pharmaron Beijing Co (STU:17Q1) Headlines

No Headlines